126 related articles for article (PubMed ID: 17051371)
21. Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Delprino L; Micari C
Am J Clin Oncol; 2006 Oct; 29(5):490-4. PubMed ID: 17023785
[TBL] [Abstract][Full Text] [Related]
22. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
23. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
[TBL] [Abstract][Full Text] [Related]
24. A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Saridaki Z; Pappas P; Souglakos J; Nikolaidou M; Vardakis N; Kotsakis A; Marselos M; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):121-8. PubMed ID: 19415279
[TBL] [Abstract][Full Text] [Related]
25. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Pignata S; Varriale E; Casella G; Iodice F; De Placido G; Perrone F; Tramontana F; Ricchi P; De Vivo R; Costanzo R; Vernaglia A; Tramontana S
Ann Oncol; 2000 May; 11(5):613-6. PubMed ID: 10907958
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
[TBL] [Abstract][Full Text] [Related]
27. Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Tassinari D; Drudi G; Panzini I; Pasini G; Arcangeli V; Fochessati F; Gianni L; Mianulli AM; Oliverio G; Pasquini E; Sartori S; Ravaioli A
Int J Clin Oncol; 2001 Dec; 6(6):279-83. PubMed ID: 11828946
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Odenike OM; Sobecks RM; Janisch L; Huo D; Zimmerman TM; Daugherty CK; Ratain MJ; Larson RA
Cancer Chemother Pharmacol; 2004 Dec; 54(6):553-61. PubMed ID: 15349753
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Tan BR; Brenner WS; Picus J; Marsh S; Gao F; Fournier C; Fracasso PM; James J; Yen-Revollo JL; McLeod HL
Ann Oncol; 2008 Oct; 19(10):1742-8. PubMed ID: 18534963
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
[TBL] [Abstract][Full Text] [Related]
32. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Zeuli M; Di Costanzo E; Sdrobolini A; Gasperoni S; Paoloni FP; Carpi A; Moscetti L; Cherubini R; Cognetti F; ;
Ann Oncol; 2001 Dec; 12(12):1737-41. PubMed ID: 11843252
[TBL] [Abstract][Full Text] [Related]
33. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
[TBL] [Abstract][Full Text] [Related]
34. Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Airoldi M; Cattel L; Passera R; Pedani F; Milla P; Zanon C
Pancreas; 2006 Jan; 32(1):44-50. PubMed ID: 16340743
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
Nemunaitis J; Cunningham CC; Vukelja S; Ruxer RL; Adams N; Rich D; Paulson AS; MacEachern JB
Cancer Invest; 2004; 22(3):360-7. PubMed ID: 15493356
[TBL] [Abstract][Full Text] [Related]
37. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
Rangwala F; Bendell JC; Kozloff MF; Arrowood CC; Dellinger A; Meadows J; Tourt-Uhlig S; Murphy J; Meadows KL; Starr A; Broderick S; Brady JC; Cushman SM; Morse MA; Uronis HE; Hsu SD; Zafar SY; Wallace J; Starodub AN; Strickler JH; Pang H; Nixon AB; Hurwitz HI
Invest New Drugs; 2014 Aug; 32(4):700-9. PubMed ID: 24711126
[TBL] [Abstract][Full Text] [Related]
39. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors.
Goetz MP; Erlichman C; Windebank AJ; Reid JM; Sloan JA; Atherton P; Adjei AA; Rubin J; Pitot H; Galanis E; Ames MM; Goldberg RM
J Clin Oncol; 2003 Oct; 21(20):3761-9. PubMed ID: 12963697
[TBL] [Abstract][Full Text] [Related]
40. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.
Ychou M; Conroy T; Seitz JF; Gourgou S; Hua A; Mery-Mignard D; Kramar A
Ann Oncol; 2003 Mar; 14(3):481-9. PubMed ID: 12598357
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]